New Study Demonstrates Allegra(R) (Fexofenadine HCL) Has Faster Onset Of Action Than Claritin(R) (Loratadine) And Clarinex(R) (Desloratadine)

Market Wire, 20050229

Full prescribing information is available by visiting the Aventis Pharmaceuticals U.S. Web site at www.aventis-us.com. Also available at this U.S. Web site are copies of this release or any recent release.

Statements in this news release other than historical information are forward-looking statements subject to risks and uncertainties. Actual results could differ materially depending on factors such as the availability of resources, the timing and effects of regulatory actions, the strength of competition, the outcome of litigation, and the effectiveness of patent protection. Additional information regarding risks and uncertainties is set forth in the current Annual Report on Form 20-F of Aventis on file with the Securities and Exchange Commission.

(1) Kaliner M, Economides A, Hale M, et al. "Relative potency of fexofenadine 180 mg, loratadine 10 mg, and placebo using a skin test model of wheal and flare suppression." Western Society of Allergy, Asthma & Immunology, January 2002.